Adult-Onset Still's Disease—A Complex Disease, a Challenging Treatment

LA Macovei, A Burlui, I Bratoiu, C Rezus… - International Journal of …, 2022 - mdpi.com
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder with an unknown
cause characterized by high-spiking fever, lymphadenopathy, hepatosplenomegaly …

Interleukin-18 binding protein in immune regulation and autoimmune diseases

SY Park, Y Hisham, HM Shin, SC Yeom, S Kim - Biomedicines, 2022 - mdpi.com
Natural soluble antagonist and decoy receptor on the surface of the cell membrane are
evolving as crucial immune system regulators as these molecules are capable of …

Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry

J Sota, A Vitale, G Lopalco, RMR Pereira… - Seminars in Arthritis and …, 2022 - Elsevier
Background/objectives Long-term efficacy and safety of tocilizumab (TCZ) in adult-onset
Still's disease (AOSD) mostly derive from small case series. Herein we report a registry …

IL-18 in Autoinflammatory diseases: focus on adult onset Still disease and macrophages activation syndrome

C Baggio, S Bindoli, I Guidea, A Doria… - International Journal of …, 2023 - mdpi.com
Interleukin-18 (IL-18) is a potent pro-inflammatory cytokine that is involved in various innate
and adaptive immune processes related to infection, inflammation, and autoimmunity …

The latest advances in the use of biological DMARDs to treat Still's disease

I Di Cola, P Ruscitti - Expert Opinion on Biological Therapy, 2024 - Taylor & Francis
Introduction Currently, the therapeutic management of Still's disease, a multisystemic
inflammatory rare disorder, is directed to target the inflammatory symptoms and signs of …

Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options

S Bindoli, C Baggio, A Doria, P Sfriso - Drugs, 2024 - Springer
Adult-onset Still's disease (AOSD) is a multisystemic complex disorder clinically
characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse …

Targeted Treatment of Diseases of Immune Dysregulation

S Mohan - Rheumatic Disease Clinics, 2023 - rheumatic.theclinics.com
The immune system provides 2 layers, innate and adaptive, of defense against pathogenic
organisms or endogenous dangers. Normally, the innate immune response is rapid (minutes …

Efficacy and Safety of Biological Drugs in Still's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

B Kilic, A Ozturk, S Karup, E Hacioglu, S Ugurlu - Rheumatology, 2024 - academic.oup.com
Objectives Still's disease is a rare autoinflammatory disorder characterized by systemic
inflammation, fever, rash, and arthritis. The term “Still's disease” covers the pediatric subtype …

Anti-IL-6 Receptor Treatment in Giant Cell Arteritis Patients Reduces Levels of IL-1β-Receptor Antagonist but Not IL-1β

JJ da Costa, L Christ, PM Villiger, M Vogel… - Rheumato, 2024 - mdpi.com
This work aimed to investigate a potential link between serum IL-1β levels in patients with
giant cell arteritis (GCA) and their responsiveness to combined anti-IL-6 receptor (IL-6R) and …

Aktuelles zum adulten Still-Syndrom: Diagnose, Therapiekonzepte und Leitlinie

S Vordenbäumen, E Feist - DMW-Deutsche Medizinische …, 2023 - thieme-connect.com
Epidemiologie Das Still-Syndrom kann sich vom Kindes-bis ins höhere Erwachsenenalter
manifestieren–mit jeweils leicht unterschiedlicher klinischer Ausprägung. Pathogenese Das …